FDA approves new type of non-opioid pain medication
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...
Business Wire3h
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigin ...
FDA approves new type of nonopioid painkiller for acute pain
The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals, NBC ...
FDA approves Vertex's non-opioid painkiller, first new kind of pain medicine in decades
The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...
pharmaphorum10mon
FDA clears AZ’s new PNH therapy Voydeya
AstraZeneca’s Voydeya has become the first oral Factor D inhibitor to be approved by the FDA as a treatment for the rare disease paroxysmal nocturnal haemoglobinuria (PNH). Voydeya (danicopan ...
pharmaphorum1y
Novartis’ Fabhalta is first FDA-cleared oral therapy for PNH
so there’s a clear need for new treatment options. The FDA approval is based on the APPLY-PNH and APPOINT-PNH trials, which showed that the drug was able to achieve “clinically meaningful ...
Hosted on MSN1mon
Novartis reports positive Phase 3b data for Fabhalta in PNH
The Swiss drugmaker said the results add to the body of evidence showing the drug is safe and effective for adults with PNH. Fabhalta was approved by the FDA in 2023 for the treatment of adults ...